The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
what they showed was that among patients who had never before had COVID, right? because they they excluded them from the analysis of of of efficacy. Among patients who never had CO before, the patients who were randomized to the vaccine had lower rates of getting COVID in the in those two months, I'm sorry, symptomatic COVID in those two months than the the people who were randomly assigned to placebo.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
So what you could what could you infer from the trial? You could infer that for two months people who had lower who had the vaccine were likely to have much less likely to get COVID for those two months symptomatic COVID for those two months. That's all you could say.